Source: Annual Congress 2013 –Biomarkers, diagnosis and outcome of respiratory infections
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
L. Fernandes, A. Mesquita, A. Arora (P.O. Caranzalem, India). Role of procalcitonin (PCT) as a marker of severity of community acquired bacterial pneumonia (CABP) compared to PSI, CRB65 abd CURB65. Eur Respir J 2013; 42: Suppl. 57, 2702

Member's Comments

No comment yet.

Related content which might interest you: Prognostic value of procalcitonin in community-acquired pneumonia Source: Eur Respir J 2011; 37: 384 Year: 2011 Could procalcitonin (PCT) be a marker of effectiveness of antibiotic treatment (ABT) in pregnant with not severe community-acquired pneumonia (CAP)? Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders Year: 2015 Performance of CURB-65 and CURB-age in community acquired pneumonia (CAP) Source: Annual Congress 2009 - Assessment of severity in respiratory infections: severity scales and biomarkers Year: 2009 Procalcitonin (PCT) and C-reactive protein (CRP) as markers of the differential diagnosis of severe community acquired pneumonia (sCAP) Source: Annual Congress 2013 –Respiratory infections: a combination of problems needing early treatment Year: 2013 Surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with community acquired pneumonia (CAP) during the treatment program Source: International Congress 2014 – Clinical problems in acute and chronic lung diseases Year: 2014 Biomarkers and community acquired pneumonia (CAP) severity Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity Year: 2010 Biomarkers and community acquired pneumonia (CAP) severity Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia Year: 2011 Can procalcitonin or C-reactive protein predict supporative lung complications and ARDS at severe community-acquired pneumonia (CAP)? Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016 Comparison of PSI, A-DROP, CURB-65, CRB-65, and SOAR indices in hospitalized patients with community acquired pneumonia Source: Annual Congress 2012 - Epidemiology: risk factors and prognosis in respiratory infections Year: 2012 The prognostic value of consecutive C-reactive protein measurements in community acquired pneumonia Source: International Congress 2015 – CAP: prognostic factors in frail patients Year: 2015 Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia Source: Annual Congress 2013 –Biomarkers, diagnosis and outcome of respiratory infections Year: 2013 Surfactant protein D (SPD) and C-reactive protein (CRP) in patient with low respiratory tract infections (LRTI) Source: Annual Congress 2013 –Lung infections: a clinical point of view Year: 2013 Role of procalcitonin in predicting severity and in-hospital mortality in patients with community-acquired pneumonia Source: International Congress 2016 – Community-acquired pneumonia: risk classes and management issues Year: 2016 Serum procalcitonin (PCT) as a marker of the severity and prognosis of ventilator-associated pneumonia (VAP) Source: Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia Year: 2007 Clinical impact of a prediction score for drug-resistance in community-onset pneumonia Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016 Surfactant protein D (SPD) like marker of effectiveness ofphosphatidylcholine treatment outcomes in patients (pts) with community acquired pneumonia (CAP) Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders Year: 2015 Correlation of procalcitonin and CRP in community-acquired pneumonia with CRB-65 score and prognosis – results from the German competence network CAPNETZ Source: Annual Congress 2006 - Inflammation markers in community-acquired pneumonia Year: 2006 Diagnostic and prognostic utility of procalcitonin (PCT) measurements in patients with hospitalized community-acquired pneumonia (CAP) Source: Annual Congress 2009 - Assessment of severity in respiratory infections: severity scales and biomarkers Year: 2009 Biomarkers and severity in community-acquired pneumonia (CAP) Source: Annual Congress 2012 - Prognostic indices in respiratory infections Year: 2012 C Reactive Protein (CRP), procalcitonin (PCT) and proadrenomedullin (Pro-ADM), as markers to discriminate bacterial, viral and mixed community acquired pneumonia (CAP) Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity Year: 2010